Elucidation of DNA Primase as a Drug Target in Leishmania donovani : Structure‐Guided Inhibitor Identification and Biochemical Validation
Chemical Biology & Drug Design · 2026-07 · 108 (1)
DOI: 10.1111/cbdd.70362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 25.07.2026. Verfasst von Deep Bhowmik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Assam University, Silchar, Assam, India. Hauptthemen laut MEDLINE: Leishmania donovani, DNA Primase, Enzyme Inhibitors, Antiprotozoal Agents. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anusandhan National Research Foundation.
Abstract (Originalsprache)
Replication is started by DNA primase, which synthesizes an oligoribonucleotide primer that DNA polymerases extend. Effective chemotherapy is still needed to manage and treat leishmaniasis, which continues to pose a threat to public health around the world. Repurposing drugs offers alternative uses for drugs with established pharmacological effects, saving money and increasing the pool of human resources available to create novel anti‐leishmanials. Here, we used a non‐radioactive primase‐pyrophosphatase assay to biochemically characterize the Leishmania donovani nuclear DNA primase ( LdPri ) subunits, followed by in silico evaluation of inhibitors targeting LdPri . The best‐evaluated inhibitors showed LdPri inhibition in vitro under conditions similar to those of the primase‐pyrophosphatase experiment. The MTT assay also confirmed the inhibitors' anti‐leishmanial properties. Parasite growth and morphological analysis were performed by culturing cells in the presence of inhibitors. Biochemical characterization revealed that LdPriS activity was unstable, but was highly stabilized upon association with LdPriL in LdPri . LdPri was found to be thermostable and possesses 3′‐terminal nucleotidyltransferase activity. Additionally, in silico and in vitro studies evaluated Pritelivir (BAY 57‐1293) as the most efficient LdPri complex inhibitor, followed by Epigallocatechin Gallate (EGCG). Moreover, kinetic studies showed that Pritelivir and EGCG exhibit competitive and uncompetitive inhibition, respectively, for both NTP and DNA substrates. Pritelivir effectively disrupted the L. donovani cell cycle, and the replication mechanism in treated promastigotes showed irregular shapes and short flagella.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Assam University, Silchar, Assam, India.
- Department of Veterinary Microbiology, Assam Veterinary and Fishery University, Khanapara, Guwahati, India.
- Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad, India.
- Department of Biotechnology, Assam University, Silchar, Assam, India.
ORCID-Profile: Deep Bhowmik, Anupama Sharma, Ravi Prakash Arya, Diwakar Kumar
Förderung
- Anusandhan National Research Foundation
Zitieren
APA
Bhowmik, D., Sharma, A., Arya, R. P., & Kumar, D. (2026). Elucidation of DNA Primase as a Drug Target in Leishmania donovani : Structure‐Guided Inhibitor Identification and Biochemical Validation. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70362
Vancouver
Bhowmik D, Sharma A, Arya RP, Kumar D. Elucidation of DNA Primase as a Drug Target in Leishmania donovani : Structure‐Guided Inhibitor Identification and Biochemical Validation. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70362
BibTeX
@article{Bhowmik2026,
author = {Bhowmik, Deep and Sharma, Anupama and Arya, Ravi Prakash and Kumar, Diwakar},
title = {Elucidation of DNA Primase as a Drug Target in Leishmania donovani : Structure‐Guided Inhibitor Identification and Biochemical Validation},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {108},
number = {1},
doi = {10.1111/cbdd.70362}
}
EUVIMED